103
Views
5
CrossRef citations to date
0
Altmetric
Original Research

Economic evaluation of therapies for patients suffering from relapsed-refractory multiple myeloma in Greece

, , &
Pages 37-48 | Published online: 10 Apr 2013

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (5)

Mir Mahmood Asrar, Deepesh P. Lad, Shankar Prinja & Dipika Bansal. (2021) A systematic review of economic evaluations of treatment regimens in multiple myeloma. Expert Review of Pharmacoeconomics & Outcomes Research 21:4, pages 799-809.
Read now
Tilman Hans Steinmetz, Moushmi Singh, Andrea Lebioda, Leah Fink, Martina Schoehl, Achim Rieth, Sebastian Gonzalez-McQuire & Monika Engelhardt. (2021) Healthcare resource utilization and costs among patients with relapsed and/or refractory multiple myeloma treated with proteasome inhibitors in real-world clinical practice in Germany. Journal of Medical Economics 24:1, pages 114-122.
Read now
Sebastian Gonzalez-McQuire, Kwee Yong, Henri Leleu, Francesco S. Mennini, Alain Flinois, Carlotta Gazzola, Paul Schoen, Marco Campioni, Lucy DeCosta & Leah Fink. (2018) Healthcare resource utilization among patients with relapsed multiple myeloma in the UK, France, and Italy. Journal of Medical Economics 21:5, pages 450-467.
Read now
Wendong Chen, Yicheng Yang, Yi Chen, Fen Du & Huan Zhan. (2016) Cost-effectiveness of bortezomib for multiple myeloma: a systematic review. ClinicoEconomics and Outcomes Research 8, pages 137-151.
Read now
Jing Wang, Hongfeng Guo & Xin Zhou. (2015) Clinical utility and patient consideration in the use of lenalidomide for multiple myeloma in Chinese patients. OncoTargets and Therapy 8, pages 1277-1284.
Read now